Emisphere Technologies, Inc.
240 Cedar Knolls Road
Suite 200
Cedar Knolls,
NJ 07927
United States - Map
Phone: 973-532-8000
Fax: 973-532-8121
Web Site: http://www.emisphere.com
| Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its eligen technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The companys product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the companys product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc. The company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Michael V. Novinski , 52
Chief Exec. Officer, Pres |
$
911.00K |
$
0 | Mr. Michael R. Garone , 50
Chief Financial Officer, Principal Accounting Officer, VP and Corp. Sec. |
$
231.00K |
$
0 | Mr. Nicholas J. Hart ,
VP of Strategy & Devel. |
$
121.00K |
$
0 | Mr. Gary M. I. Riley DVM, Ph.D., 66
VP of Nonclinical Devel. & Applied Biology |
$
307.00K |
$
0 | Mr. Patrick Osinski ,
Acting Gen. Counsel |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
Profile
